SURMOUNT-OSA: tirzepatide and obstructive sleep apnea
Evidence that treating obesity with tirzepatide can reduce the severity of sleep apnea.
Why obesity and OSA connect
Obstructive sleep apnea — repeated airway collapse during sleep — is strongly tied to excess weight, especially around the neck and upper airway. Weight loss has long been known to improve OSA, but medication-driven weight loss had not been rigorously tested as an OSA treatment until tirzepatide.
Two populations
The trial studied adults with obesity and moderate-to-severe OSA in two groups: those not using CPAP (positive airway pressure) therapy and those using it. Participants received tirzepatide or placebo, and the primary measure was change in the apnea-hypopnea index (AHI).
Fewer breathing events
Tirzepatide produced large reductions in AHI compared with placebo in both groups, alongside meaningful weight loss and improvements in related measures. For many participants, the reduction was enough to move them into a lower OSA severity category, and the drug was later recognized in labeling for this use.
Beyond weight on a scale
SURMOUNT-OSA is part of a broader story: tirzepatide's weight effects translate into improvements in weight-related conditions — here, a condition that affects sleep, daytime function and cardiovascular risk. It does not replace evaluation by a sleep specialist, and CPAP remains a mainstay for many patients.
Caveats
OSA is a medical diagnosis requiring proper testing; do not self-treat. The trial used the branded product. Compounded tirzepatide is not FDA-approved.
AHI improvement versus cure
It is important to read the OSA results precisely: tirzepatide substantially reduced the apnea-hypopnea index and moved many participants to a lower severity category, but reducing severity is not the same as curing sleep apnea in everyone. Some participants still had clinically significant OSA after treatment, and the trial does not establish that medication should replace established therapies like CPAP for all patients. What it does show is that weight-directed treatment can meaningfully improve a condition long known to respond to weight loss — now demonstrated with rigorous, objective sleep measurement rather than inferred. For patients, OSA remains a diagnosis requiring proper sleep testing and specialist guidance; tirzepatide may be one component of management for those with obesity-related OSA, not a standalone fix. The broader significance is the pattern it reinforces: tirzepatide's metabolic effects translate into improvements in weight-related diseases, with sleep apnea joining glucose, liver and cardiovascular measures.
Primary sources
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
Can tirzepatide treat sleep apnea?
In SURMOUNT-OSA, tirzepatide substantially reduced the apnea-hypopnea index in adults with obesity and moderate-to-severe OSA, with and without CPAP. It is a medical decision made with a clinician.
Does it replace CPAP?
Not necessarily. CPAP remains a mainstay for many; tirzepatide reduced OSA severity but care should be guided by a sleep specialist.
What is the AHI?
The apnea-hypopnea index counts breathing interruptions per hour of sleep — the standard measure of OSA severity that tirzepatide reduced in the trial.